Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rigel PharmaceuticalsFRA:RI2 -1.65%24 Debt-to-Equity is 0.11 as of Mar. 2026, which is 76% below its 10-year median of 0.45. GuruFocus rates FRA:RI2 with a GF Score™ of 24/100 and a GF Value™ of €24.03 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 966 Biotechnology companies, Rigel Pharmaceuticals ranks better than 57.97% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Rigel Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
FRA:RI2'
s Debt-to-Equity Range Over the Past 10 Years
Min: -9.69 Med: 0.45 Max: 18.24
Current: 0.11
During the past 13 years, the highest Debt-to-Equity Ratio of Rigel Pharmaceuticals was 18.24. The lowest was -9.69. And the median was 0.45.
FRA:RI2's Debt-to-Equity is ranked better than 57.97% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:RI2: 0.11
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Rigel Pharmaceuticals Debt-to-Equity Related Terms
Rigel Pharmaceuticals Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Rigel Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RI2 vs SGP, OCS, GYRE: Debt-to-Equity Comparison
For the Biotechnology subindustry, Rigel Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (FRA:RI2) has a Debt-to-Equity of 0.11 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rigel Pharmaceuticals and its competitors. This is 76% below median its historical median of 0.45. According to the industry distribution chart, Rigel Pharmaceuticals ranks #406 out of 966 companies in the Biotechnology industry, placing it in the top 42%.
Is Rigel Pharmaceuticals' Debt-to-Equity too high?
Rigel Pharmaceuticals' current Debt-to-Equity of 0.11 is 76% below median its 10-year median of 0.45. The Biotechnology industry median Debt-to-Equity is 0.16. Rigel Pharmaceuticals' value of 0.11 is 31.3% below this industry median. Based on the distribution chart, Rigel Pharmaceuticals ranks #406 out of 966 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rigel Pharmaceuticals has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Debt-to-Equity compare to SGP and OCS?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #406 out of 966 companies for Debt-to-Equity. This puts Rigel Pharmaceuticals in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Rigel Pharmaceuticals' value of 0.11 is 31.3% below this benchmark. While the company's 10-year median is 0.45 vs. the industry median of 0.16, Rigel Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rigel Pharmaceuticals's current Debt-to-Equity of 0.11 is 31.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Rigel Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rigel Pharmaceuticals's current Debt-to-Equity is 0.11, which is 76% below median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rigel Pharmaceuticals (FRA:RI2) is currently considered Significantly Overvalued. The stock's GF Value™ is €24.03, compared to a current price of €32.85 — trading 36.7% above its estimated fair value. The current Debt-to-Equity is 0.11, which is 76% below median its 10-year median of 0.45 and 31.3% below the Biotechnology industry median of 0.16. Rigel Pharmaceuticals' overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Debt-to-Equity is 0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?
Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued.
The current stock price of €32.85 is trading 36.7% above its estimated GF Value™ of €24.03.
GuruFocus considers Rigel Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:RI2:
Debt-to-Equity: 0.11 (76% below median its 10-year median of 0.45)
GF Value™: €24.03 vs. price of €32.85 (36.7% above fair value)
Industry Position: 31.3% below the Biotechnology median (#406 of 966)
No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
24GF Score
Get the complete analysis for FRA:RI2
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RI2 has been successfully added to your 
